Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Fig. 2

a Duration of treatment for full analysis set population (N = 89). b Best percentage change from baseline in target lesion size for full analysis set population based on an independent radiological review committee assessment (N = 74). CR, complete response; PR, partial response; SD, stable disease; CPD, confirmed progressive disease; UE, unevaluable; UPD, unconfirmed progressive disease; PD, progressive disease. Note Out of 89 patients in the full analysis set, five patients did not have measurable target lesion at baseline per central review, eight patients withdrew before first response assessment and two patients had disease progression on the basis of physical examination by investigators without radiographic record

Back to article page